Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward  Takuma Uo, Cynthia Sprenger  European Urology 

Slides:



Advertisements
Similar presentations
Volume 68, Issue 6, Pages (December 2015)
Advertisements

Volume 59, Issue 2, Pages (February 2011)
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
A new therapeutic antibody masks ErbB2 to its partners
Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi  European Urology 
Testosterone Therapy in Men With Prostate Cancer
Volume 72, Issue 5, Pages (November 2017)
Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth  Abraham Morgentaler, Abdulmaged.
Volume 61, Issue 6, Pages (June 2012)
Testosterone and Prostate Cancer: Revisiting Old Paradigms
Volume 53, Issue 5, Pages (May 2008)
Volume 64, Issue 4, Pages (October 2013)
Volume 68, Issue 2, Pages (August 2015)
Let the Games Begin (with EAU Approval)
Volume 71, Issue 5, Pages (May 2017)
Volume 52, Issue 3, Pages (September 2007)
Prostate Cancer Epidemic in Sight?
Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer  Olav Erich Yri, Trine Bjoro, Sophie D.
The Global Risk of Bladder Cancer: Let's Just Do Something About It!
Volume 74, Issue 1, Pages (July 2018)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate.
Volume 72, Issue 2, Pages (August 2017)
Volume 65, Issue 1, Pages (January 2014)
Volume 71, Issue 1, Pages 1-3 (January 2017)
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Prostate Cancer Detection: A View of the Future
Volume 66, Issue 3, Pages (September 2014)
Obesity and Prostate Cancer: A Role for Adipokines
Counselling the Prostate Cancer Patient
Volume 70, Issue 4, Pages (October 2016)
Laurent Boccon-Gibod  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
Volume 70, Issue 1, Pages e27-e28 (July 2016)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 61, Issue 6, Pages (June 2012)
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Volume 72, Issue 1, Pages (July 2017)
Volume 66, Issue 2, Pages (August 2014)
therapy and to block androgen action
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Testosterone Measurement in Patients with Prostate Cancer
Volume 74, Issue 2, Pages (August 2018)
Volume 67, Issue 1, Pages (January 2015)
Michèle Algarté-Génin, Olivier Cussenot, Pierre Costa  European Urology 
Volume 50, Issue 5, Pages (November 2006)
Volume 53, Issue 6, Pages (June 2008)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 55, Issue 3, Pages (March 2009)
Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion- Positive Prostate Cancers  Yu Chen, Charles L. Sawyers  Cancer Cell  Volume.
A new therapeutic antibody masks ErbB2 to its partners
Testicular Cancer Variations in Time and Space in Europe
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Volume 53, Issue 1, Pages (January 2008)
Volume 71, Issue 4, Pages (April 2017)
European Urology is “Your” Journal
Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg 
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
The Start-Up of the Platinum Journal: A Fascinating Challenge
Development of Androgen Receptor Antagonists with Promising Activity in Castration- Resistant Prostate Cancer  Howard C. Shen, Steven P. Balk  Cancer Cell 
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
William G. Nelson, Michael C. Haffner, Srinivasan Yegnasubramanian 
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson 
Volume 53, Issue 2, Pages (February 2008)
Annika Berntsen, Poul F. Geertsen, Inge Marie Svane  European Urology 
Nat. Rev. Urol. doi: /nrurol
Volume 51, Issue 5, Pages (May 2007)
European Urology Oncology
Presentation transcript:

Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward  Takuma Uo, Cynthia Sprenger  European Urology  Volume 73, Issue 5, Pages 724-726 (May 2018) DOI: 10.1016/j.eururo.2017.12.020 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 Androgen receptor (AR) isoforms form homo- and heterodimers. Abiraterone limits the availability of dihydrotestosterone (DHT), while enzalutamide (Enza) antagonizes the ligand-binding domain (LBD) of AR, thus inhibiting the genomic actions of full-length AR (AR-FL). AR variants (AR-Vs) that retain the entire N-terminal domain and DNA-binding domain, may have nuclear localization and be constitutively active, while others may require liganded AR-FL or constitutively active AR-Vs to be localized in the nucleus, and thus exhibit “conditional” activities. The presence of multiple combinations of dimerization may diversify AR signaling, thereby contributing to resistance to current anti-AR therapies. European Urology 2018 73, 724-726DOI: (10.1016/j.eururo.2017.12.020) Copyright © 2017 European Association of Urology Terms and Conditions